Sign in to view content

Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO

Nikhil K Bommakanti, MD

Video
Published 2024

Related

Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration
David A. Eichenbaum, MD, FASRS
Updates from the Field
2018
Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from the Pegcetacoplan Clinical Program
Diana V Do, MD, FASRS
Updates from the Field
2025
Assessment on Pre-to-Post Switching Efficacy and Safety of SB15 (Proposed Aflibercept Biosimilar): Post Hoc Analysis of a Phase 3 Clinical Trial
Srinivas Reddy Sadda, MD
Annual Meeting Talks
2024

Category: AMD-Neovascular

See more